EUVIMEDEUVIMED entdecken
Open Access

Association Between Copayment Assistance, Insurance Type, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs

Morgan R L Lichtenstein iD, Melissa P Beauchemin iD, Rohit Raghunathan, Shing Lee iD, Sahil D Doshi iD, Cynthia Law, Melissa K Accordino iD, Elena B Elkin iD, Jason D Wright iD, Dawn L Hershman iD

JCO Oncology Practice · 2024

DOI: 10.1200/op.23.00205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2024. Verfasst von Morgan R L Lichtenstein und 9 weiteren Autor:innen. Beteiligte Einrichtung: Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Oral anticancer drugs (OACDs) have become increasingly prevalent over the past decade. OACD prescriptions require coordination between payers and providers, which can delay drug receipt. We examined the association between insurance type, pursuit of copayment assistance, pursuit of prior authorization (PA), and time to receipt (TTR) for new OACD prescriptions. METHODS We prospectively collected data on new OACD prescriptions for adult oncology patients from January 1, 2018, to December 31, 2019, including demographic and clinical characteristics, insurance type, and pursuit of PA and copayment assistance. TTR was defined as the number of days from prescription to OACD receipt. We summarized TTR using cumulative incidence and compared TTR by insurance type, pursuit of copayment assistance, and PA activity using the log-rank test. RESULTS Our cohort of 1,024 patients was 53% male, and 40% were younger than 65. Twenty-six percent had commercial insurance only, 16% had Medicaid only, and 59% had Medicare with or without additional insurance. Eighty-six percent of prescriptions were successfully received. Across all prescriptions, 69% involved PA activity, and 21% involved the copayment assistance process. In unadjusted analyses, prescriptions involving the copayment assistance process had longer TTR compared with those not involving assistance (log-rank P value = .005) and OACDs covered by Medicare/commercial insurance had a longer TTR compared with Medicaid (log-rank P value = .006). The PA process was not associated with TTR (log-rank P value = .124). CONCLUSION The process for obtaining OACDs is complex. The copayment assistance process and Medicare/commercial insurance are associated with delayed TTR. New policies are needed to reduce time to OACD receipt.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsAgedAdultHumansMaleUnited StatesFemaleMedicarePrior AuthorizationMedicaid

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY.
  • Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
  • School of Nursing, Columbia University Irving Medical Center, New York, NY.
  • Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY.
  • Division of Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY.

ORCID-Profile: Morgan R L Lichtenstein, Melissa P Beauchemin, Shing Lee, Sahil D Doshi, Melissa K Accordino, Elena B Elkin, Jason D Wright, Dawn L Hershman

Förderung

  • NCI NIH HHS

Zitieren

APA

Lichtenstein, M. R. L., Beauchemin, M. P., Raghunathan, R., Lee, S., Doshi, S. D., Law, C., Accordino, M. K., Elkin, E. B., Wright, J. D., & Hershman, D. L. (2024). Association Between Copayment Assistance, Insurance Type, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs. JCO Oncology Practice. https://doi.org/10.1200/op.23.00205

Vancouver

Lichtenstein MRL, Beauchemin MP, Raghunathan R, Lee S, Doshi SD, Law C, et al. Association Between Copayment Assistance, Insurance Type, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs. JCO Oncology Practice. 2024. doi:10.1200/op.23.00205

BibTeX
@article{Lichtenstein2024,
  author = {Lichtenstein, Morgan R L and Beauchemin, Melissa P and Raghunathan, Rohit and Lee, Shing and Doshi, Sahil D and Law, Cynthia and Accordino, Melissa K and Elkin, Elena B and Wright, Jason D and Hershman, Dawn L},
  title = {Association Between Copayment Assistance, Insurance Type, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs},
  journal = {JCO Oncology Practice},
  year = {2024},
  doi = {10.1200/op.23.00205}
}
Kostenlos starten →